Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Bird’s Eye View Of The Rare Disease R&D Landscape

Executive Summary

The number of drugs in development for rare diseases have increased by 56%, with the number of rare diseases on the development map also increasing by 23% in just three years, demonstrating ongoing interest and seemingly increased enthusiasm for research within these areas of high unmet needs.

You may also be interested in...

Hemophilia And Rare Diseases Drive European Mid-Pharmas Sobi And Recordati

Sweden’s Swedish Orphan Biovitrum and Italy’s Recordati are looking towards hemophilia and rare diseases to keep up the growth of their businesses, and Q3 results have highlighted the Swedish company in particular as a potential takeover target.

Gene Therapies: Waiting To Emerge From The Bottle

Slowly but surely, gene therapy projects are winning back confidence from the industry and as investment increases, so increase the reports on progress in this area; from sensational claims of restoring sight, to slightly more spurious claims of reversing the aging process.

Orphan Drug Pricing: More Dialogue And Collaboration Needed, Says EURORDIS

Pharmaceutical companies, payers and other stakeholders need to work more collaboratively if the problems surrounding the pricing and reimbursement of orphan medicines are to be tackled successfully in Europe, says the rare disease organization EURORDIS.


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts